IOL Chemicals and Pharmaceuticals Reports Q1 FY23 Results
- Net profit of the Company at Rs 34.9 Cr against Rs. 27.8 Cr QoQ and Rs. 67 Cr YoY
- Total Income stood at Rs 570.2 Cr against Rs. 579.4 Cr QoQ and Rs 524.2 Cr YoY
- EBITDA at Rs. 61.2 Cr as compared to Rs. 50.1 Cr QoQ and Rs 115.9 Cr YoY
10th August, 2022, Mumbai:
IOL Chemicals and Pharmaceuticals Limited, a leading manufacturer of pharmaceutical (APIs) and specialty chemicals reported results for the first quarter ended June 30, 2022 as highlighted herein below:
Q1FY23 Standalone Financial Highlights (Rs in Crore)
| Particulars | Q1 FY23 | Q4 FY22 | QoQ % Change |
| Total Income | 570.2 | 579.4 | -1.6 |
| EBITDA | 61.2 | 50.1 | 22.2 |
| EBITDA Margin (%) | 10.7 | 8.6 | 24.4 |
| PAT | 34.9 | 27.8 | 25.5 |
Commenting on the performance of the Company during the quarter, Dr Sanjay Chaturvedi, Executive Director & CEO said, “Over the next few years, our focus will be on diversifying into other speciality chemical products and increase the share of non-Ibuprofen business. The investment planned in setting up a new plant will aid the Company in strength en ing its position in both, Domestic and Export markets, thereby helping in improving our market share. Over the course of next few quarters, the Company’s plan to explore new geographies and de-risk the business with continuous backward integration model will play out leading to improvement in revenue as well as profitability.”
“Various business challenges of softening demand, rising inputs costs and volatility in chemical prices are slowly getting normalised as can be seen from recovery in EBITDA margins. However, we believe that the challenges are a temporary phenomenon. The robust global demand on specialty chemicals fronts owing to shift in market share from China would benefit the sector over next few years”, Dr Chaturvedi said.
As one of largest manufacturers of Ethyl Acetate, the Company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 12 0,000 MTPA from 100,000 MTPA before the end of current fiscal. The investm ent of Rs 15 Crore for this capex is being funded through internal accruals only. Ethyl Acetate is wi dely used in Printing & Packing Industry, Adhesives, Agroch emicals & Pesticides industry, pharmaceuticals indu stry and cosmetics industry. The Company will also be making further in-roads into western markets of India thr ough a new plant for specialty chemicals and pharmaceuticals intermediates. This project, which is expected to be completed in 18 months, will require invest ment of Rs 300 crore. Through this plant, the Company’s objec tive is to increase its market share in the dom estic market as well as cater to international customers.
About IOL Chemicals and Pharmaceuticals Limited (IOLCP)
Company was established in 1986, listed on National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164) is one of the leading pharmaceutical (APIs) Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, antidiabetes, anti- cholesterol and anti-platelets.The Company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paraceta mol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.
Company is World’s largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with 17 MW captive Co-Generation plant for self -reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.
IOLCP’s overseas customers are spread out across several countries including UK, Belgium, Hungry, Spain, Ger many, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.
Disclaimer:
This document may contain statement which reflect management’s current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to diff er materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments
